Novel ophthalmic pharmaceuticals drive innovation, improve outcomes: Understanding nuances of reimbursement for novel, sustained-release ophthalmic drugs can help maximize the opportunity for patients and practice

Saved in:
Bibliographic Details
Published inOphthalmology times Vol. 46; no. 12; pp. 25 - 27
Main Author Nijm, Lisa M
Format Magazine Article
LanguageEnglish
Published Intellisphere, LLC 15.07.2021
Subjects
Bimatoprost
Dexamethasone
Innovations
Ophthalmology
Transdermal medication
Online AccessGet full text

Cover

More Information
ISSN:0193-032X
2150-7333